Cargando…

A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer

This study expands the understanding of the role of target therapy in improving survival of patients with mCRC based on real-world study results. These data represent potential survival outcomes of Taiwanese patients with mCRC in clinical practice. CRC is the most commonly diagnosed cancer and the t...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Sheng-Chieh, Lin, Chun-Chi, Teng, Hao-Wei, Lin, Hung-Hsin, Chang, Shih-Ching, Lan, Yuan-Tzu, Wang, Huann-Sheng, Yang, Shung-Haur, Chen, Wei-Shone, Jiang, Jeng-Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968042/
https://www.ncbi.nlm.nih.gov/pubmed/35372058
http://dx.doi.org/10.3389/fonc.2022.808808
_version_ 1784678961960189952
author Huang, Sheng-Chieh
Lin, Chun-Chi
Teng, Hao-Wei
Lin, Hung-Hsin
Chang, Shih-Ching
Lan, Yuan-Tzu
Wang, Huann-Sheng
Yang, Shung-Haur
Chen, Wei-Shone
Jiang, Jeng-Kai
author_facet Huang, Sheng-Chieh
Lin, Chun-Chi
Teng, Hao-Wei
Lin, Hung-Hsin
Chang, Shih-Ching
Lan, Yuan-Tzu
Wang, Huann-Sheng
Yang, Shung-Haur
Chen, Wei-Shone
Jiang, Jeng-Kai
author_sort Huang, Sheng-Chieh
collection PubMed
description This study expands the understanding of the role of target therapy in improving survival of patients with mCRC based on real-world study results. These data represent potential survival outcomes of Taiwanese patients with mCRC in clinical practice. CRC is the most commonly diagnosed cancer and the third leading cause of cancer-related death in Taiwan. The aim of this study was to evaluate the efficacy of target therapy in combination with chemotherapy for mCRC in Taiwan. This was a real-world, retrospective, observational study in patients diagnosed with mCRC (N=1583). A total of 792 patients received chemotherapy plus target therapy (anti-EGFR therapy, n=180; anti-VEGF therapy, n=612) and 791 patients who received chemotherapy alone. Overall survival (OS) and progression-free survival (PFS) were examined. For RAS wild-type patients, the median OS (mOS) was 34.3 months in the EGFR L (left-sided colon) group, 27.3 months in the VEGF L group, 18.4 months in VEGF R (right-sided colon) group, and 13.8 months in EGFR R group (P<0.001). Median PFS (mPFS) was 9.8 months in the EGFR L group, 8.9 months in the VEGF L group, 6.8 months in VEGF R group, and 5.8 months in EGFR R group. In patients with a RAS mutation, mOS was 25.4 months in the VEGF L group and 19.4 months in the VEGF R group (P=0.167). Judicious treatment allocation in Taiwanese patients with mCRC can result in an mOS of 34.3 months using cetuximab plus chemotherapy for left-sided tumors. An mOS of 48.5 months can be achieved using cetuximab plus chemotherapy in the neoadjuvant setting in mCRC patients with left-sided tumors. This study expands our understanding of the role of target therapy in improving survival of mCRC patients based on real-world study results.
format Online
Article
Text
id pubmed-8968042
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89680422022-04-01 A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer Huang, Sheng-Chieh Lin, Chun-Chi Teng, Hao-Wei Lin, Hung-Hsin Chang, Shih-Ching Lan, Yuan-Tzu Wang, Huann-Sheng Yang, Shung-Haur Chen, Wei-Shone Jiang, Jeng-Kai Front Oncol Oncology This study expands the understanding of the role of target therapy in improving survival of patients with mCRC based on real-world study results. These data represent potential survival outcomes of Taiwanese patients with mCRC in clinical practice. CRC is the most commonly diagnosed cancer and the third leading cause of cancer-related death in Taiwan. The aim of this study was to evaluate the efficacy of target therapy in combination with chemotherapy for mCRC in Taiwan. This was a real-world, retrospective, observational study in patients diagnosed with mCRC (N=1583). A total of 792 patients received chemotherapy plus target therapy (anti-EGFR therapy, n=180; anti-VEGF therapy, n=612) and 791 patients who received chemotherapy alone. Overall survival (OS) and progression-free survival (PFS) were examined. For RAS wild-type patients, the median OS (mOS) was 34.3 months in the EGFR L (left-sided colon) group, 27.3 months in the VEGF L group, 18.4 months in VEGF R (right-sided colon) group, and 13.8 months in EGFR R group (P<0.001). Median PFS (mPFS) was 9.8 months in the EGFR L group, 8.9 months in the VEGF L group, 6.8 months in VEGF R group, and 5.8 months in EGFR R group. In patients with a RAS mutation, mOS was 25.4 months in the VEGF L group and 19.4 months in the VEGF R group (P=0.167). Judicious treatment allocation in Taiwanese patients with mCRC can result in an mOS of 34.3 months using cetuximab plus chemotherapy for left-sided tumors. An mOS of 48.5 months can be achieved using cetuximab plus chemotherapy in the neoadjuvant setting in mCRC patients with left-sided tumors. This study expands our understanding of the role of target therapy in improving survival of mCRC patients based on real-world study results. Frontiers Media S.A. 2022-03-17 /pmc/articles/PMC8968042/ /pubmed/35372058 http://dx.doi.org/10.3389/fonc.2022.808808 Text en Copyright © 2022 Huang, Lin, Teng, Lin, Chang, Lan, Wang, Yang, Chen and Jiang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Huang, Sheng-Chieh
Lin, Chun-Chi
Teng, Hao-Wei
Lin, Hung-Hsin
Chang, Shih-Ching
Lan, Yuan-Tzu
Wang, Huann-Sheng
Yang, Shung-Haur
Chen, Wei-Shone
Jiang, Jeng-Kai
A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer
title A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer
title_full A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer
title_fullStr A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer
title_full_unstemmed A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer
title_short A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer
title_sort long-term and large-scale real-world study in taiwan: efficacy of target therapy in stage iv colorectal cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968042/
https://www.ncbi.nlm.nih.gov/pubmed/35372058
http://dx.doi.org/10.3389/fonc.2022.808808
work_keys_str_mv AT huangshengchieh alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer
AT linchunchi alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer
AT tenghaowei alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer
AT linhunghsin alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer
AT changshihching alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer
AT lanyuantzu alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer
AT wanghuannsheng alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer
AT yangshunghaur alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer
AT chenweishone alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer
AT jiangjengkai alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer
AT huangshengchieh longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer
AT linchunchi longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer
AT tenghaowei longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer
AT linhunghsin longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer
AT changshihching longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer
AT lanyuantzu longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer
AT wanghuannsheng longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer
AT yangshunghaur longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer
AT chenweishone longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer
AT jiangjengkai longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer